Effect of acute citrate load on markers of bone metabolism in healthy volunteers

Vox Sanguinis

Volumn 97, Issue 4, 2009, Pages 324-329

  Chen, Y ^a,b   Bieglmayer, C ^a   Hocker P ^a   Dettke, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Fujian Blood Center   (China)

Author keywords

Apheresis; Bone markers; Citrate

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; CALCIUM ION; CARBOXY TERMINAL TELOPEPTIDE; CITRIC ACID; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE;

ADULT; APHERESIS; ARTICLE; BONE METABOLISM; BONE TURNOVER; CALCIUM BALANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; HUMAN; HUMAN EXPERIMENT; HYPOCALCEMIA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ANTICOAGULANTS; BIOLOGICAL MARKERS; BONE RESORPTION; CITRIC ACID; COLLAGEN TYPE I; CROSS-OVER STUDIES; HUMANS; MALE; OSTEOCALCIN; OSTEOGENESIS; PARATHYROID HORMONE; PEPTIDES; TIME FACTORS;

EID: 70350033613     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2009.01202.x     Document Type: Article

References (33)

1. Winters JL : Complications of donor apheresis. J Clin Apher 2006 21 : 132 141
2. Mcleod BC, Price TH, Owen H, Ciavarella D, Sniecinski I, Randels MJ, Smith JW : Frequency of immediate adverse effects associated with apheresis donation. Transfusion 1998 38 : 938 943
3. Dettke M, Buchta C, Bieglmayer C, Kainberger F, Macher M, Hocker P : Short and long term effects of citrate on bone metabolism and bone mineral density in healthy plateletpheresis donors. J Clin Apher 2003 18 : 87
4. Bolan CD, Cecco SA, Yau YY, Wesley RA, Oblitas JM, Rehak NN, Leitman SF : Randomized placebo-controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metabolic effects. Transfusion 2003 43 : 1414 1422
5. Herrmann M, Herrmann W : The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. Clin Chem Lab Med 2004 42 : 1384 1389
6. Hamwi A, Ganem AH, Grebe C, Kerschan-Schindl K, Preisinger E, Boschitsch E, Bieglmayer C : Markers of bone turnover in postmenopausal women receiving hormone replacement therapy. Clin Chem Lab Med 2001 39 : 414 417
7. Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, Gamwell Henriksen E, Qvist P, Alexandersen P, Bang Henriksen D : Serum crosslaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000 26 : 505 511
8. Okabe R, Inaba M, Nakatsuka K, Miki T, Naka H, Moriguchi A, Nishizawa Y : Significance of serum crosslaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab 2004 22 : 127 131
9. Capeller B, Caffier H, Sutterlin MW, Dietl J : Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res 2003 23 : 1011 1015
10. Nowak Z, Konieczna M, Wankowicz Z: [ Tartrate-resistant acid phosphatase - TRAP 5b - as a novel marker of bone resortption in patients with irreversible renal failure treated with dialysis.] Pol Merkur Lekarski 2004 17 : 138 141 (in Polish)
11. Han KO, Choi JT, Choi HA, Moon IG, Yim CH, Park WK, Yoon HK, Han IK : The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. Clin Endocrinol 2005 62 : 349 353
12. Swaminathan R : Biochemical markers of bone turnover. Clin Chim Acta 2001 313 : 95 105
13. Peichl P, Griesmacherb A, Marteau R, Hejc S, Kumpan W, Müller MM, Bröll H : Serum crosslaps in comparison to serum osteocalcin and urinary bone resorption markers. Clin Biochem 2001 34 : 131 139
14. Wichers M, Schmidt E, Bidlingmaier F : Diurnal rhythm of crosslaps in human serum. Clin Chem 1999 45 : 1858 1860
15. Gundberg CM, Markowitz ME, Mizruchi M, Rosen JF : Osteocalcin in human serum: a circadian rhythm. J Clin Endocrinol Metab 1985 4 : 736 739
16. Council of Europe : Guide to the Preparation, Use and Quality Assurance of Blood Components, Recommendation No. R (95) 15; 9th edn. Strasbourg, France : Council of Europe Publishing, 2003.
17. Nordin BEC : Assessment of calcium excretion from the urinary calcium/creatinine ratio. Lancet 1959 2 : 368 371
18. Rogers A, Eastell R : Circulating osteoprotegerin and receptor activator for nuclear factor κB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005 90 : 6323 6331
19. Seibel MJ : Biochemical markers of bone turnover. part I. biochemistry and variability. Clin Biochem Rev 2005 26 : 97 122
20. Tarquini R, Mazzoccoli G, Dolenti S : Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health. Biomed Pharmacother 2005 59 : S225 S228
21. Bjarnason NH, Henriksen EE, Alexandersen P, Christgau S, Henriksen DB, Christiansen C : Mechanism of circadian variation in bone resorption. Bone 2002 30 : 307 313
22. Mcsheehy PM, Chambers TJ : Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology 1986 118 : 824 828
23. Perry HM, Skogen W, Chappel J, Kahn AJ, Wilner G, Teitelbaum SL : Partial characterization of a parathyroid hormone-stimulated resorption factor from osteoblast-like cells. Endocrinology 1989 125 : 2075 2082
24. Locklin RM, Khosla S, Turner RT, Riggs BL : Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 2003 89 : 180 190
25. Poole K-ES, Reeve J : Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol 2005 5 : 612 617
26. Hofbauer LC, Kuehne CA, Viereck V : The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 2004 4 : 268 275
27. Takayanagi H : Inflammatory bone destruction and osteoimmunology. J Periodont Res 2005 40 : 287 293
28. Kanamaru F, Iwai H, Ikeda T, Nakajima A, Ishikawa I, Azuma M : Expression of membrane-bound and soluble receptor activator of NF-κB ligand (RANKL) in human T cells. Immunol Lett 2004 94 : 239 246
29. Weitzmann MN, Cenci S, Rifas L, Haug J, Dipersio J, Pacifici R : T cell activation induces human osteoclast formation via receptor activator of nuclear factor factor kappa B ligand-dependent and -independent mechanisms. J Bone Miner Res 2001 16 : 328 337
30. Klinger M, Alexiewicz JM, Linker-Israeli M, Pitts TO, Gaciong Z, Fadda GZ, Massry SG : Effect of parathyroid hormone on human T cell activation. Kidney Int 1990 37 : 1543 1551
31. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA : PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 2004 19 : 235 244
32. Lee SK, Lorenzo JA : Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999 140 : 3552 3561
33. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A : Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 2004 34 : 187 194